Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
6/1/1998
1.
Phase III Randomized, Double-Blind Study of Daily x 14 Subcutaneous IL-11 vs Placebo for Severe Chemotherapy-Induced Thrombocytopenia (Summary Last Modified 06/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
16 and over
Pharmaceutical / Industry
GENE-C9504-14
NCI-V96-0810
Last Modified:
11/1/1998
 
First Published:
9/1/1998
2.
Phase III Randomized Study of Interleukin-11 for Chemotherapy-Induced Thrombocytopenia in Patients With Solid Tumors or Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Closed
18 and over
Pharmaceutical / Industry
MRMC-CTCA-9705
GENE-C9707-14, NCI-V98-1440
Last Modified:
6/21/2007
 
First Published:
6/1/1998
3.
Phase II Study of Recombinant Human Interleukin-11 with Sargramostim (GM-CSF) for Acute Myeloid Leukemia Patients Receiving High-Dose Cytarabine During Induction and Consolidation Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Completed
18-55
NCI
E-3997
E3997
Last Modified:
4/1/2002
 
First Published:
12/1/1999
4.
Phase II Study of Interleukin-11 With Filgrastim (G-CSF) in the Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors (Summary Last Modified 04/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
70 and under
NCI
FHCRC-1365.00
NCI-G99-1622, NCT00004157
5.
Interleukin 11, Thrombocytopenia, CML, Imatinib in CML Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care
Closed
Not specified
Other
2004-0113
NCT00493181
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute